Selected research
Industry Research
Prostaglandin E2 Receptor EP4 Subtype Industry Research Report 2026
Market perspective
The global Prostaglandin E2 Receptor EP4 Subtype market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Prostaglandin E2 Receptor EP4 Subtype market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Prostaglandin E2 Receptor EP4 Subtype market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Prostaglandin E2 Receptor EP4 Subtype market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Prostaglandin E2 Receptor EP4 Subtype include Eisai Co Ltd, Eli Lilly and Co, Rottapharm Biotech Srl, RaQualia Pharma Inc, Ono Pharmaceutical Co Ltd and Kaken Pharmaceutical Co Ltd, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Prostaglandin E2 Receptor EP4 Subtype market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Prostaglandin E2 Receptor EP4 Subtype.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Prostaglandin E2 Receptor EP4 Subtype Market by Company
Eisai Co Ltd
Eli Lilly and Co
Rottapharm Biotech Srl
RaQualia Pharma Inc
Ono Pharmaceutical Co Ltd
Kaken Pharmaceutical Co Ltd
Prostaglandin E2 Receptor EP4 Subtype Segment by Type
ONO-4232
KAG-308
ER-886046
Grapiprant
E-7046
Others
Prostaglandin E2 Receptor EP4 Subtype Segment by Application
Breast Cancer
Chronic Pain
Acute Pain
Allergies
Lung Cancer
Others
Prostaglandin E2 Receptor EP4 Subtype Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostaglandin E2 Receptor EP4 Subtype market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostaglandin E2 Receptor EP4 Subtype and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostaglandin E2 Receptor EP4 Subtype.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Prostaglandin E2 Receptor EP4 Subtype companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ONO-4232
- KAG-308
- ER-886046
- Grapiprant
- E-7046
- Others
Applications
- Breast Cancer
- Chronic Pain
- Acute Pain
- Allergies
- Lung Cancer
- Others
Companies covered
- Eisai Co Ltd
- Eli Lilly and Co
- Rottapharm Biotech Srl
- RaQualia Pharma Inc
- Ono Pharmaceutical Co Ltd
- Kaken Pharmaceutical Co Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Prostaglandin E2 Receptor EP4 Subtype by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 ONO-4232
- 2.2.3 KAG-308
- 2.2.4 ER-886046
- 2.2.5 Grapiprant
- 2.2.6 E-7046
- 2.2.7 Others
- 2.3 Prostaglandin E2 Receptor EP4 Subtype by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Breast Cancer
- 2.3.3 Chronic Pain
- 2.3.4 Acute Pain
- 2.3.5 Allergies
- 2.3.6 Lung Cancer
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Prostaglandin E2 Receptor EP4 Subtype Breakdown Data by Type
- 3.1 Global Prostaglandin E2 Receptor EP4 Subtype Historic Market Size by Type (2021-2026)
- 3.2 Global Prostaglandin E2 Receptor EP4 Subtype Forecasted Market Size by Type (2027-2032)
4 Prostaglandin E2 Receptor EP4 Subtype Breakdown Data by Application
- 4.1 Global Prostaglandin E2 Receptor EP4 Subtype Historic Market Size by Application (2021-2026)
- 4.2 Global Prostaglandin E2 Receptor EP4 Subtype Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Prostaglandin E2 Receptor EP4 Subtype Market Perspective (2021-2032)
- 5.2 Global Prostaglandin E2 Receptor EP4 Subtype Growth Trends by Region
- 5.2.1 Global Prostaglandin E2 Receptor EP4 Subtype Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Prostaglandin E2 Receptor EP4 Subtype Historic Market Size by Region (2021-2026)
- 5.2.3 Prostaglandin E2 Receptor EP4 Subtype Forecasted Market Size by Region (2027-2032)
- 5.3 Prostaglandin E2 Receptor EP4 Subtype Market Dynamics
- 5.3.1 Prostaglandin E2 Receptor EP4 Subtype Industry Trends
- 5.3.2 Prostaglandin E2 Receptor EP4 Subtype Market Drivers
- 5.3.3 Prostaglandin E2 Receptor EP4 Subtype Market Challenges
- 5.3.4 Prostaglandin E2 Receptor EP4 Subtype Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Prostaglandin E2 Receptor EP4 Subtype Players by Revenue
- 6.1.1 Global Top Prostaglandin E2 Receptor EP4 Subtype Players by Revenue (2021-2026)
- 6.1.2 Global Prostaglandin E2 Receptor EP4 Subtype Revenue Market Share by Players (2021-2026)
- 6.2 Global Prostaglandin E2 Receptor EP4 Subtype Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Prostaglandin E2 Receptor EP4 Subtype Head Office and Area Served
- 6.4 Global Prostaglandin E2 Receptor EP4 Subtype Players, Product Type & Application
- 6.5 Global Prostaglandin E2 Receptor EP4 Subtype Manufacturers Established Date
- 6.6 Global Prostaglandin E2 Receptor EP4 Subtype Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Prostaglandin E2 Receptor EP4 Subtype Market Size (2021-2032)
- 7.2 North America Prostaglandin E2 Receptor EP4 Subtype Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2021-2026)
- 7.4 North America Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Prostaglandin E2 Receptor EP4 Subtype Market Size (2021-2032)
- 8.2 Europe Prostaglandin E2 Receptor EP4 Subtype Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2021-2026)
- 8.4 Europe Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Market Size (2021-2032)
- 9.2 Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Prostaglandin E2 Receptor EP4 Subtype Market Size (2021-2032)
- 10.2 South America Prostaglandin E2 Receptor EP4 Subtype Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2021-2026)
- 10.4 South America Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Market Size (2021-2032)
- 11.2 Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eisai Co Ltd
- 12.1.1 Eisai Co Ltd Company Information
- 12.1.2 Eisai Co Ltd Business Overview
- 12.1.3 Eisai Co Ltd Revenue in Prostaglandin E2 Receptor EP4 Subtype Business (2021-2026)
- 12.1.4 Eisai Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
- 12.1.5 Eisai Co Ltd Recent Developments
- 12.2 Eli Lilly and Co
- 12.2.1 Eli Lilly and Co Company Information
- 12.2.2 Eli Lilly and Co Business Overview
- 12.2.3 Eli Lilly and Co Revenue in Prostaglandin E2 Receptor EP4 Subtype Business (2021-2026)
- 12.2.4 Eli Lilly and Co Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
- 12.2.5 Eli Lilly and Co Recent Developments
- 12.3 Rottapharm Biotech Srl
- 12.3.1 Rottapharm Biotech Srl Company Information
- 12.3.2 Rottapharm Biotech Srl Business Overview
- 12.3.3 Rottapharm Biotech Srl Revenue in Prostaglandin E2 Receptor EP4 Subtype Business (2021-2026)
- 12.3.4 Rottapharm Biotech Srl Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
- 12.3.5 Rottapharm Biotech Srl Recent Developments
- 12.4 RaQualia Pharma Inc
- 12.4.1 RaQualia Pharma Inc Company Information
- 12.4.2 RaQualia Pharma Inc Business Overview
- 12.4.3 RaQualia Pharma Inc Revenue in Prostaglandin E2 Receptor EP4 Subtype Business (2021-2026)
- 12.4.4 RaQualia Pharma Inc Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
- 12.4.5 RaQualia Pharma Inc Recent Developments
- 12.5 Ono Pharmaceutical Co Ltd
- 12.5.1 Ono Pharmaceutical Co Ltd Company Information
- 12.5.2 Ono Pharmaceutical Co Ltd Business Overview
- 12.5.3 Ono Pharmaceutical Co Ltd Revenue in Prostaglandin E2 Receptor EP4 Subtype Business (2021-2026)
- 12.5.4 Ono Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
- 12.5.5 Ono Pharmaceutical Co Ltd Recent Developments
- 12.6 Kaken Pharmaceutical Co Ltd
- 12.6.1 Kaken Pharmaceutical Co Ltd Company Information
- 12.6.2 Kaken Pharmaceutical Co Ltd Business Overview
- 12.6.3 Kaken Pharmaceutical Co Ltd Revenue in Prostaglandin E2 Receptor EP4 Subtype Business (2021-2026)
- 12.6.4 Kaken Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
- 12.6.5 Kaken Pharmaceutical Co Ltd Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst